You are here:

enzalutamide (Xtandi)

Advice

following a full submission

enzalutamide (Xtandi®) is accepted for use within NHS Scotland.

Indication under review: Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.

In one randomised, double-blind, phase III clinical study, enzalutamide significantly increased overall survival compared with placebo.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of enzalutamide.  This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

Drug Details

Drug Name: enzalutamide (Xtandi)
SMC Drug ID: 911/13
Manufacturer: Astellas Pharma Ltd
Indication: Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.
BNF Category:
Submission Type: Full submission
Status: Accepted
Date Advice Published: 11 November 2013

Back